APA (7th ed.) Citation

HS, B., MA, B., SR, G., EL, T., J, V., CD, R., . . . RA, Y. (2013). Tophus burden reduction with pegloticase: Results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis research & therapy, 15(5), R137. https://doi.org/10.1186/ar4318

Chicago Style (17th ed.) Citation

HS, Baraf, Becker MA, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, Rehrig CD, Ottery FD, Sundy JS, and Yood RA. "Tophus Burden Reduction with Pegloticase: Results from Phase 3 Randomized Trials and Open-label Extension in Patients with Chronic Gout Refractory to Conventional Therapy." Arthritis Research & Therapy 15, no. 5 (2013): R137. https://doi.org/10.1186/ar4318.

MLA (9th ed.) Citation

HS, Baraf, et al. "Tophus Burden Reduction with Pegloticase: Results from Phase 3 Randomized Trials and Open-label Extension in Patients with Chronic Gout Refractory to Conventional Therapy." Arthritis Research & Therapy, vol. 15, no. 5, 2013, p. R137, https://doi.org/10.1186/ar4318.